GABARAP缺失介导多发性骨髓瘤对免疫原性化疗的耐药
研究整合患者转录组数据与钙网蛋白相互作用蛋白分析,发现GABARAP缺失使硼替佐米处理后肿瘤细胞死亡不被感知为免疫原性。GABARAP位于17p,其缺失降低钙网蛋白暴露、树突状细胞吞噬及抗肿瘤T细胞反应,低GABARAP独立关联更短生存。雷帕霉素上调自噬可恢复GABARAP敲除细胞的钙网蛋白暴露与免疫原性细胞死亡信号。
要点
- GABARAP缺失阻碍硼替佐米诱导的免疫原性细胞死亡信号。
- 低GABARAP独立关联多发性骨髓瘤患者更短生存与肿瘤免疫浸润减少。
- 雷帕霉素恢复GABARAP敲除细胞的自噬、高尔基形态与钙网蛋白暴露。
核心结论
- GABARAP缺失通过减少自噬和改变高尔基体形态阻断钙网蛋白囊泡运输,使硼替佐米处理的骨髓瘤细胞死亡不被感知为免疫原性。
- 作者认为将免疫原性细胞死亡诱导剂(如硼替佐米)与自噬诱导剂(如雷帕霉素)联用可能改善低GABARAP(以del(17p)形式常见)多发性骨髓瘤患者的结局。
研究设计与样本
- 研究整合患者转录组数据与钙网蛋白蛋白相互作用分析,并在体外和体内进行功能验证。
主要发现
- GABARAP缺失在体外和体内损害濒死骨髓瘤细胞表面钙网蛋白暴露,减少树突状细胞对肿瘤细胞的吞噬及后续抗肿瘤T细胞反应。
- 低GABARAP独立关联多发性骨髓瘤患者更短生存和肿瘤免疫浸润减少。
- 机制上,GABARAP缺失通过减少自噬和改变高尔基体形态阻断免疫原性细胞死亡信号,导致钙网蛋白下游囊泡运输缺陷。
- 雷帕霉素上调自噬可恢复GABARAP敲除细胞接受硼替佐米处理后的高尔基体形态、钙网蛋白暴露和免疫原性细胞死亡信号。
关键数值与推荐
- GABARAP位于染色体17p,在高危多发性骨髓瘤患者中常被缺失。
临床怎么用
- 作者认为将免疫原性细胞死亡诱导剂(如硼替佐米)与自噬诱导剂(如雷帕霉素)联用可能改善低GABARAP多发性骨髓瘤患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunogenic cell death (ICD) is a form of cell death by which cancer treatments can induce a clinically relevant antitumor immune response in a broad range of cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib is an ICD inducer and creates durable therapeutic responses in patients. However, eventual relapse and resistance to bortezomib appear inevitable. Here, by integrating patient transcriptomic data with an analysis of calreticulin (CRT) protein interactors, we found that GABA type A receptor-associated protein (GABARAP) is a key player whose loss prevented tumor cell death from being perceived as immunogenic after bortezomib treatment. GABARAP is located on chromosome 17p, which is commonly deleted in patients with high risk MM. GABARAP deletion impaired the exposure of the eat-me signal CRT on the surface of dying MM cells in vitro and in vivo, thus reducing tumor cell phagocytosis by dendritic cells and the subsequent antitumor T-cell response. Low GABARAP was independently associated with shorter survival in patients with MM and reduced tumor immune infiltration. Mechanistically, we found that GABARAP deletion blocked ICD signaling by decreasing autophagy and altering Golgi apparatus morphology, with consequent defects in the downstream vesicular transport of CRT. Conversely, upregulating autophagy using rapamycin restored Golgi morphology, CRT exposure, and ICD signaling in GABARAPKO cells undergoing bortezomib treatment. Therefore, coupling an ICD inducer, such as bortezomib, with an autophagy inducer, such as rapamycin, may improve patient outcomes in MM, in which low GABARAP in the form of del(17p) is common and leads to worse outcomes.
引用
- Gulla A, Morelli E, Johnstone M, et al. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024. PMID: 38551812. doi:10.1182/blood.2023022777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。